In 2023, FDA approves far fewer first generic drugs than in recent years
Is the fall from the patent cliff finally over?
The FDA has significantly raised the bar when it comes to approving more and more generic drugs every year, making the pharmaceuticals market significantly cheaper in the process. But so far in 2023, one important metric that the agency tracks — the number of first generics to hit the market (i.e. first competition for a brand name drug) — has stalled for unknown reasons.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
